GlassScriptPhysician profile
Pratik D Bhattacharya
NPI 1528212768
$11,797.91
in general payments reported to CMS, 2019-2025
42 companies · $4,334 in 2025
The $4,334 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $27.10 · 2021: $221 · 2022: $1,531 · 2023: $1,758 · 2024: $3,687 · 2025: $4,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,506 · Consulting Fee: $150 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,506.07 |
| Consulting Fee | $150.00 |
| Education | $123.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,276.12 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,137.53 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $762.63 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lundbeck LLC | $656.20 | 2019-2025 | Vyepti, Rexulti |
| Biogen, INC. | $648.43 | 2023-2025 | Tysabri, Vumerity, Avonex |
| Abbvie INC. | $639.50 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $588.01 | 2023-2025 | |
| Celgene Corporation | $495.71 | 2022-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $457.58 | 2023-2025 | |
| Argenx US, INC. | $417.09 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Astrazeneca Pharmaceuticals LP | $388.89 | 2021-2024 | Andexxa, Wainua |
| Takeda Pharmaceuticals U.S.A., INC. | $364.74 | 2022-2025 | Hyqvia, Gammagard |
| Genzyme Corporation | $359.77 | 2022-2025 | |
| Catalyst Pharmaceuticals, INC. | $313.56 | 2024-2025 | |
| Lilly USA, LLC | $293.67 | 2022-2025 | Kisunla, Emgality, Amyvid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $261.20 | 2022-2025 | Hizentra |
| Tg Therapeutics, INC. | $256.81 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $243.97 | 2023-2025 | Nuedexta, Rexulti |
| Vanda Pharmaceuticals INC. | $236.24 | 2024-2025 | Ponvory |
| Eisai INC. | $223.60 | 2023-2025 | |
| Genentech USA, INC. | $200.25 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Alnylam Pharmaceuticals INC. | $199.60 | 2022-2025 | Onpattro, Amvuttra |
| Alexion Pharmaceuticals, INC. | $189.01 | 2024-2025 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $149.99 | 2022 | |
| Medtronic, INC. | $147.63 | 2022 | |
| Tanabe Pharma America, INC. | $97.64 | 2024-2025 | Radicava |
| Acadia Pharmaceuticals INC | $90.90 | 2023-2025 | Nuplazid |
| Neurelis, INC. | $81.76 | 2024-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $70.75 | 2023-2024 | Aptiom |
| Axsome Therapeutics, INC. | $69.60 | 2025 | Symbravo |
| Xeris Pharmaceuticals, INC. | $63.54 | 2025 | Keveyis |
| Corium, LLC | $59.19 | 2022-2023 | Adlarity |
| Merck Sharp & Dohme LLC | $57.43 | 2022-2023 | Zerbaxa, Dificid |
| Avanir Pharmaceuticals, INC. | $43.57 | 2022 | |
| Cycle Pharmaceuticals INC | $43.11 | 2025 | Tascenso Odt, Bafiertam |
| Amgen INC. | $39.85 | 2022 | |
| Azurity Pharmaceuticals, INC. | $35.51 | 2024 | Horizant |
| Octapharma USA, INC. | $29.51 | 2025 | Panzyga |
| Biohaven Pharmaceuticals, INC. | $28.68 | 2021 | |
| Aucta Pharmaceuticals, INC. | $27.89 | 2025 | Motpoly Xr |
| E.R. Squibb & Sons, L.L.C. | $27.45 | 2024 | Zeposia |
| Hospira, INC. | $23.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratik Bhattacharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.